Pemetrexed
- Generic Name
- Pemetrexed
- Brand Names
- Alimta, Ciambra, Pemfexy, Pemrydi Rtu, Pemetrexed Fresenius Kabi, Pemetrexed Baxter, Pemetrexed Krka, Pemetrexed medac, Pemetrexed Accord, Pemetrexed Sandoz, Armisarte (previously Pemetrexed Actavis)
- Drug Type
- Small Molecule
- Chemical Formula
- C20H21N5O6
- CAS Number
- 137281-23-3
- Unique Ingredient Identifier
- 04Q9AIZ7NO
- Background
Pemetrexed is a chemotherapy drug that is manufactured and marketed by Eli Lilly and Company under the brand name Alimta. It is indicated for use in combination with cisplatin for the treatment of patients with malignant pleural mesothelioma whose disease is either unresectable or who are otherwise not candidates for curative surgery. Its use in non-small ce...
- Indication
Pemetrexed is indicated for the treatment of the following conditions:
Non-squamous non-small cell lung cancer (NSCLC)
Malignant pleural mesothelioma
- Associated Conditions
- Metastatic Cervical Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer, Metastatic Urothelial Carcinoma (UC), Ovarian Cancer, Locally advanced nonsquamous non-small cell lung cancer, Recurrent, metastatic Non-squamous Non-small-cell Lung Cancer (NSQ NSCLC), Unresectable Malignant Pleural Mesothelioma (MPM), Unresectable Thymoma
- Associated Therapies
- Monotherapy
Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) and Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009)
- Conditions
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 520
- Registration Number
- NCT06305754
- Locations
- 🇨🇳
Anhui Provincial Cancer Hospital ( Site 3132), Hefei, Anhui, China
🇨🇳Beijing Peking Union Medical College Hospital-pneumology department ( Site 3107), Beijing, Beijing, China
🇨🇳The First Affiliated Hospital of Soochow University-Respiratory Department ( Site 3118), Suzhou, Jiangsu, China
Intra-pemetrexed Plus Third-generation Small Molecule TKI Drugs (e.g. 'Osimertinib') Versus Third-generation Small Molecule TKI Drugs Alone for Leptomeningeal Metastasis From Epidermal Growth Factor Receptor Mutation-Positive Non-Small-cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2024-03-12
- Last Posted Date
- 2024-03-12
- Lead Sponsor
- Guangzhou Medical University
- Target Recruit Count
- 100
- Registration Number
- NCT06304441
- Locations
- 🇨🇳
The Third People's Hospital of Huizhou (Huizhou Hospital of Guangzhou Medical University), Huizhou, Guangdong, China
Intrathecal Pemetrexed for Leptomeningeal Metastasis From Lung Adenocarcinoma That Progressed After Osimertinib.
- First Posted Date
- 2024-03-06
- Last Posted Date
- 2024-03-06
- Lead Sponsor
- Guangzhou Medical University
- Target Recruit Count
- 36
- Registration Number
- NCT06296745
A Study to Evaluate PK, Efficacy, and Safety of BAT3306 Plus Chemo and Compare With Keytruda®(EU/US) in Participants With IV nqNSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-02-28
- Last Posted Date
- 2024-08-05
- Lead Sponsor
- Bio-Thera Solutions
- Target Recruit Count
- 676
- Registration Number
- NCT06280196
- Locations
- 🇨🇳
Huizhou Central People's Hospital, Huizhou, Guangdong, China
A Phase 2 Study of EIK1001 in Combo With Pembrolizumab and Chemotherapy in Patients With Stage 4 NSCLC
- Conditions
- Interventions
- First Posted Date
- 2024-02-07
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Eikon Therapeutics
- Target Recruit Count
- 70
- Registration Number
- NCT06246110
- Locations
- 🇺🇸
Tennessee Cancer Specialists, Knoxville, Tennessee, United States
🇺🇸Southern Cancer Care, Daphne, Alabama, United States
🇺🇸Ironwood Cancer and Research Center, Chandler, Arizona, United States
Study to Evaluate Adverse Events, Optimal Dose, and Change in Disease Activity, With Livmoniplimab in Combination With Budigalimab Plus Chemotherapy Versus IV Infused Pembrolizumab Plus Chemotherapy in Adult Participants With Untreated Metastatic Non-Squamous Non-Small Cell Lung Cancer (NSCLC)
- Conditions
- Interventions
- First Posted Date
- 2024-02-01
- Last Posted Date
- 2024-11-28
- Lead Sponsor
- AbbVie
- Target Recruit Count
- 840
- Registration Number
- NCT06236438
- Locations
- 🇺🇸
University of Kansas Medical Center /ID# 263196, Westwood, Kansas, United States
🇺🇸Memorial Hospital West /ID# 262221, Pembroke Pines, Florida, United States
🇺🇸Bond Clinic /ID# 262611, Winter Haven, Florida, United States
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan Extension
- First Posted Date
- 2024-01-19
- Last Posted Date
- 2024-05-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 378
- Registration Number
- NCT06212752
- Locations
- 🇯🇵
Miyagi Cancer Center ( Site 4401), Natori, Miyagi, Japan
🇯🇵Fujita Health University ( Site 4406), Toyoake, Aichi, Japan
🇯🇵Kurume University Hospital ( Site 4412), Kurume, Fukuoka, Japan
Study of RAS(ON) Inhibitor Combinations in Patients with Advanced RAS-mutated NSCLC
- First Posted Date
- 2023-12-08
- Last Posted Date
- 2024-12-05
- Lead Sponsor
- Revolution Medicines, Inc.
- Target Recruit Count
- 484
- Registration Number
- NCT06162221
- Locations
- 🇺🇸
Cancer Specialists of North Florida, St Augustine, Florida, United States
🇺🇸Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇩🇪Thoraxklinik Heidelberg gGmbH - Universitätsklinikum Heidelberg, Heidelberg, Germany
A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery
- Conditions
- Interventions
- First Posted Date
- 2023-12-07
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Regeneron Pharmaceuticals
- Target Recruit Count
- 180
- Registration Number
- NCT06161441
- Locations
- 🇺🇸
Mid Florida Hematology and Oncology Center, Orange City, Florida, United States
🇺🇸Virginia Cancer Care Specialist, PC, Fairfax, Virginia, United States
🇦🇺St Vincents Hospital, Fitzroy, Victoria, Australia
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
- Conditions
- Interventions
- First Posted Date
- 2023-11-30
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Boehringer Ingelheim
- Target Recruit Count
- 270
- Registration Number
- NCT06151574
- Locations
- 🇵🇹
Hospital CUF Porto, Porto, Portugal
🇺🇸Scripps Cancer Center Torrey Pines, La Jolla, California, United States
🇺🇸Valkyrie Clinical Trials, Los Angeles, California, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.